公开(公告)号：US20240209085A1

公开(公告)日：2024-06-27

申请号：US17927071

申请日：2021-05-31

Applicant: AMGEN INC.

Inventor： Sophia K. Khaldoyanidi ,  Dirk Nagorsen

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/02

CPC classification number: C07K16/2809 ,  A61P35/02 ,  C07K16/2803 ,  A61K2039/545 ,  C07K2317/31 ,  C07K2317/622

Abstract: The present invention provides a bispecific construct comprising a first binding domain specifically binding to a target such as CD33 and a second binding domain specifically binding to an effector such as CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered in one or more treatment cycles of more than 14 days applying a step dosing comprising at least two, preferably steps, wherein the first step is higher than the second step with respect to the previous dosage, and wherein the second step is higher than the optional but preferred third step with respect to the previous dosage, a treatment cycle optionally followed by a period without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.

公开(公告)号：US20210301017A1

公开(公告)日：2021-09-30

申请号：US17264373

申请日：2019-07-29

Applicant: AMGEN RESEARCH (MUNICH) GMBH ,  AMGEN INC.

Inventor： Dirk Nagorsen ,  Bhakti Mehta ,  Peter Kufer ,  Roman Kischel ,  Sophia K. Khaldoyanidi

IPC: C07K16/28 ,  A61K45/06 ,  A61P35/02

Abstract: The present invention provides a bispecific antibody construct comprising a first binding domain specifically binding to a target such as CD33 and a second binding domain specifically binding to an effector such as CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered in one or more treatment cycles of more than 14 days applying a step dosing comprising at least two steps, a treatment cycle optionally followed by a period without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific antibody construct and the use of such bispecific antibody construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.

公开(公告)号：US20230146593A1

公开(公告)日：2023-05-11

申请号：US17910698

申请日：2021-03-12

Applicant: AMGEN INC.

Inventor： Sophia K. Khaldoyanidi ,  Dirk Nagorsen ,  Tara Arvedson ,  Suresh Agarwal ,  Vijay Vishesh Upreti ,  Steven Yea

IPC: A61K39/395 ,  A61K38/17 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K38/1793 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention relates to medical combination products comprising (i) at least one antibody construct comprising at least one domain which binds to a target antigen expressed on the surface of a cell and at least one other domain which binds to CD3 as well as (ii) at least one molecule that is inhibitor/antagonist of TNF/TNFR reducing TNF/TNFR signaling and/or an inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling, wherein a first dose of said inhibitor/antagonist is administered before administration of a first dose of said antibody construct. Furthermore, the invention provides therapeutic and preventive methods and medical uses of said combination products, as well as a kit comprising said at least one antibody construct and at least one antagonist/inhibitor of TNF or IL6 or its cognate receptor, wherein the interaction of said antagonist/inhibitor of TNF or an inhibitor/antagonist of IL6 with its cognate receptor reduces, mitigates, prevents, or treats cytokine release syndrome.